AbbVie received a Complete Response Letter from the FDA regarding its application for TrenibotE, a fast-acting botulinum neurotoxin serotype E for treating moderate to severe glabellar lines. The FDA's concerns were limited to manufacturing process details, with no safety or efficacy issues raised, and no additional clinical trials requested. AbbVie plans to respond to the FDA's feedback in the coming months. TrenibotE is notable for its rapid onset and shorter duration compared to existing type A botulinum toxins, potentially appealing to patients seeking shorter-term effects.
AbbVie announced final Phase 3 results from the CLL14 trial showing that a fixed-duration venetoclax plus obinutuzumab treatment significantly improves progression-free survival (PFS) in previously untreated chronic lymphocytic leukemia (CLL) patient...
AbbVie shares have risen over 53% in 2024 driven by strong sales of immunology drugs Skyrizi and Rinvoq, which are offsetting Humira's decline faster than expected. However, the company faces challenges with a negative shareholders’ equity of -$6.6 b...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
Verizon, Chevron, and AbbVie have all raised their dividends in 2026, appealing to retirees and income-focused investors seeking reliable payouts amid market volatility. Verizon offers a high yield of around 6% with strong cash flow and recent growth...
